Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $58 to $68.
Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $58 to $68.